Cerevel Therapeutics Holdings Future Growth
Future criteria checks 0/6
Cerevel Therapeutics Holdings is forecast to grow earnings and revenue by 12.5% and 68.3% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be -69.1% in 3 years.
Key information
12.5%
Earnings growth rate
17.8%
EPS growth rate
| Biotechs earnings growth | 20.7% |
| Revenue growth rate | 68.3% |
| Future return on equity | -69.1% |
| Analyst coverage | Good |
| Last updated | 05 Mar 2024 |
Recent future growth updates
Recent updates
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02
Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Dosing underway in Cerevel Therapeutics' tavapadon trials for Parkinson’s disease
Oct 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 81 | -571 | -448 | -453 | 6 |
| 12/31/2025 | N/A | -551 | -496 | -534 | 7 |
| 12/31/2024 | N/A | -456 | -297 | -436 | 9 |
| 12/31/2023 | N/A | -433 | -346 | -342 | N/A |
| 9/30/2023 | N/A | -393 | -336 | -332 | N/A |
| 6/30/2023 | N/A | -397 | -343 | -340 | N/A |
| 3/31/2023 | N/A | -388 | -323 | -320 | N/A |
| 12/31/2022 | N/A | -352 | -297 | -293 | N/A |
| 9/30/2022 | N/A | -318 | -263 | -258 | N/A |
| 6/30/2022 | N/A | -280 | -227 | -222 | N/A |
| 3/31/2022 | N/A | -243 | -218 | -210 | N/A |
| 12/31/2021 | N/A | -225 | -189 | -179 | N/A |
| 9/30/2021 | N/A | -196 | -184 | -168 | N/A |
| 6/30/2021 | N/A | -173 | -167 | -144 | N/A |
| 3/31/2021 | N/A | -146 | -146 | -125 | N/A |
| 12/31/2020 | N/A | -148 | -137 | -118 | N/A |
| 9/30/2020 | N/A | -175 | -124 | -112 | N/A |
| 6/30/2020 | N/A | -172 | -116 | -111 | N/A |
| 3/31/2020 | N/A | -151 | -97 | -94 | N/A |
| 12/31/2019 | N/A | -128 | -72 | -71 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CERE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CERE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CERE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CERE is forecast to have no revenue next year.
High Growth Revenue: CERE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CERE is forecast to be unprofitable in 3 years.